Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function

Abstract

A randomized, double-blind, placebo-controlled trial was conducted to (1) evaluate efficacy and safety of transdermal testosterone gel (AndroGel) for hypogonadal men in Taiwan, and (2) observe improvements in sexual function through international index of erectile function (IIEF) scores. Eligible hypogonadal men were randomized to receive 50 mg/day transdermal testosterone gel (TTG) or placebo for 3 months. Primary end point was change from baseline in total testosterone (TT) and free testosterone (FT). Secondary end points were change from baseline in serum hormone levels (such as dihydrotestosterone (DHT), estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex-hormone-binding globulin (SHBG)) and changes in IIEF scores. Safety evaluations included adverse events (AEs) and skin irritation assessment. Compared with baseline, the TTG group (n=20) had statistically significant increases in mean TT levels at month 1 (P=0.024) and month 2 (P=0.025), but no significant changes at month 3. TT levels in the placebo group (n=18) showed no statistically significant change at any visit. Changes in FT levels paralleled changes in TT levels in both groups. TTG group IIEF scores were significantly increased at month 3 (P=0.01), compared with a decline in placebo scores. No drug-related AEs occurred in the TTG group; the placebo group had 2 AEs (mild skin rash). In conclusion, TTG effectively restores serum TT and FT levels to a normal physiological range for hypogonadal men in Taiwan and improves sexual function.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mulhall JP, Valenzuela R, Aviv N, Parker M . Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004; 63: 348–353.

    Article  PubMed  Google Scholar 

  2. Meikle AW, Matthias D, Hoffman AR . Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU Int 2004; 93: 789–795.

    Article  CAS  PubMed  Google Scholar 

  3. Henzl MR, Loomba PK . Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 2003; 48: 525–540.

    CAS  PubMed  Google Scholar 

  4. Snyder PJ, Lawrence DA . Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51: 1335–1339.

    Article  CAS  PubMed  Google Scholar 

  5. Swerdloff RS, Wang C . Three-year follow-up of androgen treatment in hypogonadal men:preliminary report with testosterone gel. Aging Male 2003; 6: 207–211.

    Article  CAS  PubMed  Google Scholar 

  6. Davis SS, Viosca SP, Guralnik M, Windsor C, Buttiglieri MW, Baker JD et al. Evaluation of impotence in older men. West J Med 1985; 142: 499–505.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningam G et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839–2853.

    CAS  PubMed  Google Scholar 

  8. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098.

    Article  CAS  PubMed  Google Scholar 

  9. Bagatell CJ, Bremner WJ . Androgens in men: uses and abuses. N Engl J Med 1996; 334: 707–714.

    Article  CAS  PubMed  Google Scholar 

  10. Bhasin S . Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 1221–1225.

    CAS  PubMed  Google Scholar 

  11. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673–2681.

    Article  CAS  PubMed  Google Scholar 

  12. Rolf C, Knie U, Lemmnitz G, Nieschlag E . Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol 2002; 56: 637–641.

    Article  CAS  Google Scholar 

  13. Bals-Pratsch M, Knuth UA, Yoon Y-D, Nieschlag E . Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986; 2: 943–946.

    Article  CAS  PubMed  Google Scholar 

  14. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site vs four sites. J Clin Endocrinol Metab 2000; 85: 964–969.

    CAS  PubMed  Google Scholar 

  15. Schultheiss D, Hiltl D-M, Meschi MR, Machtens SA, Truss MC, Stief CG et al. Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction. World J Urol 2000; 18: 431–435.

    Article  CAS  PubMed  Google Scholar 

  16. Aversa A, Isidor AM, Spara G, Lenzi A, Fabbri A . Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 58: 632–638.

    Article  CAS  Google Scholar 

  17. Park KH, Kim SW, Kim KD, Paick J-S . Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327–333.

    Article  CAS  PubMed  Google Scholar 

  18. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I . Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861–1868.

    Article  CAS  PubMed  Google Scholar 

  19. Ding AQ, Stallone JN . Testosterone-induced relaxation of rat aorta is androgen specific and involves K+ channel activation. J Appl Physiol 2001; 91: 2742–2750.

    Article  CAS  PubMed  Google Scholar 

  20. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A . Role of androgens in erectile function. J Urol 2004; 171: 2358–2362.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was partly sponsored by Oriental Europharma Company Ltd., Taiwan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T I S Hwang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chiang, H., Hwang, T., Hsui, Y. et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 19, 411–417 (2007). https://doi.org/10.1038/sj.ijir.3901562

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901562

Keywords

  • free testosterone
  • hypogonadism
  • international index of erectile function (IIEF)
  • international prostate symptom score (IPSS)
  • total testosterone

This article is cited by

Search

Quick links